Condition: Non-Small Cell Lung Cancer · Sponsor: ETOP IBCSG Partners Foundation
ARCH is a randomised, stratified, multicentre, phase III trial. Protocol treatment consists of cemiplimab, 350 mg i.v., every 3 weeks, for 4 cycles, followed by 700 mg i.v., every 6 weeks for 6 cycles or until relapse or unacceptable toxicities, whichever occurs first. The primary objective of the study is to determine the efficacy of adjuvant cemiplimab, as measured by disease-free survival, in patients without prior adjuvant platinum-based chemotherapy, compared to observation without adjuvant treatment. The primary objective will be assessed in patients with tumours with centrally confirmed PD-L1 expression of ≥1%.
This description comes directly from the study's public registry record.
Heidi Roschitzki, PhD · +41 31 511 94 00 · heidi.roschitzki@etop.ibcsg.org
Susanne Roux · +41 31 511 94 00 · ARCH@etop.ibcsg.org
Always discuss trial participation with your own doctor first.
| Wien AKH | Vienna, Austria | Not Yet Recruiting |
| North Estonia Medical Centre Foundation | Talinn, Estonia | Recruiting |
| CHU d'Angers | Angers, France | Not Yet Recruiting |
| Centre hospitalier d'Avignon | Avignon, France | Not Yet Recruiting |
| Evangelische Lungenklinik Berlin | Buch, Germany | Not Yet Recruiting |
| Ruhrlandklinik Essen | Essen, Germany | Recruiting |
| LMU München | München, Germany | Recruiting |
| Pius Hospital, University Medicine Oldenburg | Oldenburg, Germany | Not Yet Recruiting |
| Cork University Hospital | Cork, Ireland | Not Yet Recruiting |
| Beaumont Hospital | Dublin, Ireland | Recruiting |
| St James's Hospital | Dublin, Ireland | Recruiting |
| St. Vincent's University Hospital | Dublin, Ireland | Not Yet Recruiting |
+ 23 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06931717